This invention describes adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37°C that can be produced at remarkably low costs. This invention describes vaccine compositions and formulations to treat and prevent urinary tract infections caused by gram-negative bacteria including Escherichia coli and multi-drug resistant E. coli. This invention also describes methods of administration of said vaccine compositions and formulations and methods of treatment to prevent and treat urinary tract infections caused by gram-negative bacteria including E. coli and multi-drug resistant E. coli.
